循环瘤DNA和副本数量的改变对复发/逆转性生殖细胞瘤的临床结果的影响,这些瘤接受了救援性高剂量化疗
Milena Urbini1, Thomas F Eleveld2, Maurizio Polano3
1Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy.
概括
循环无细胞DNA分析揭示了瘤分数 (TF) 和拷贝数变化 (CNAs) 作为预测复发性/耐药性生殖细胞瘤 (rGCT) 结果的关键生物标志物. 高TF和特定CNA识别出预后不佳的患者,指导救援疗法选择.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 生物标志物发现发现
背景情况:
- 复发性/耐药性生殖细胞瘤 (rGCT) 在一线化疗后构成了挑战.
- 高剂量化疗 (HDCT) 是一个救援选择,但预测反应至关重要.
- 确定HDCT可靠的生物标志物对于患者管理至关重要.
研究的目的:
- 确定循环生物标志物,预测经过HDCT的rGCT患者的临床反应和结果.
- 评估血中瘤分数 (TF) 和副本数变化 (CNAs) 的预后值.
主要方法:
- 来自69名接受HDCT治疗和26名接受常规剂量化疗 (CDCT) 治疗的GCT患者的血样本的浅整基因组测序.
- 使用ichorCNA. 的TF和CNA的量化.
- TF和CNA资料与无进展生存率 (PFS) 和整体生存率 (OS) 的相关性.
- 使用外部组织GCT队列验证CNA资料的验证.
主要成果:
- 在非精髓瘤患者中,高基线TF与更差的整体存活率 (OS) 相关,这在HDCT和CDCT队列中得到证实.
- 血CNA剖析确定了特定的变化 (例如,3p增益,9q增益,11q增益,6q损失),与糟糕的HDCT结果有关,特别是在胚胎外组织学中.
- 无监督的CNA配置文件集群确定了一个高风险子组,PFS和OS明显较差.
结论:
- 无细胞DNA分析为rGCT提供了有价值的预后信息.
- 高基线TF和特定的CNA模式是不良结果的指标,可以指导救援疗法选择.
- 在高TF患者中,HDCT可能比CDCT更有效,这表明rGCT治疗的风险分层更精细.
更多相关视频
06:53Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
9.2K
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.6K
相关概念视频
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K